Cathelicidin peptide
LL-37
LL-37 after one dose: 50% at ~4 h, 25% at 8 h, 12.5% at 12 h.
Drawn from the half-life in the app's model, ~4 h. The model's figures
- Compound
- LL-37
- Symbol
- LL
- Family
- Healing peptides
- Parts
- 13
- References
- 18
- Checked
- Last reviewed . Sources are listed below.
Overview
LL-37 is the only human cathelicidin, a 37-residue peptide named after its N-terminal leucine-leucine motif, according to a 2025 review by Voronko and colleagues.1 Its precursor is human cationic antimicrobial peptide-18 (hCAP18).1 The app lists it as a cathelicidin peptide with an emerging evidence grade.
The largest trial of the peptide itself in the tables, a phase IIb trial in 148 treated patients with venous leg ulcers, reported that its efficacy analysis in the full study population "did not identify any significant improvement in healing" with LL-37 against placebo.2
FDA's compounding page lists cathelicidin LL-37 among bulk drug substances nominated but withdrawn and states that FDA lacks sufficient safety-related information about it.6
How it works
Sources in this part
What LL-37 is
LL-37 is an amphipathic peptide of 37 amino acid residues, 16 of them charged, with a net positive charge of +6, according to the 2025 Voronko review in the International Journal of Molecular Sciences.1 The same review describes the active peptide as released from the hCAP18 precursor by proteolytic cleavage, mediated by enzymes such as neutrophil elastase and serine proteinase 3.1 Vandamme and colleagues, Cellular Immunology, 2012, summarised cathelicidins as having antibacterial, antifungal and antiviral functions, immunomodulatory effects, and a capacity to induce wound healing and angiogenesis.7
In cells and animals
For how LL-37 acts on bacterial membranes, the Voronko review states that "LL-37 appears to have a hybrid mode of action", with features of both the toroidal pore and the carpet-like mechanisms.1 The review also states that LL-37 "can damage the plasma membranes of erythrocytes, lymphocytes, and fibroblasts in vitro at concentrations similar to those required for antimicrobial activity".1
In people
The introduction to the 2021 venous leg ulcer trial states that endogenous LL-37 "was abundantly present in acute wounds, but was absent in chronic wounds" and that the mechanism by which LL-37 increases healing "is not fully understood".2
Pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~4 h
- Bioavailability
- 95%
- Typical dose
- 50–100 mcg
- Route
- SubQ
- Time to peak
- ~30 min
A search of PubMed on 16 November 2026 for LL-37 with pharmacokinetic or half-life in the title or summary text returned 8 records, and none of their titles names a human pharmacokinetic study of LL-37 itself.
| Parameter | App figure | Source figures |
|---|---|---|
| Half-life | ~4 hours | None of the sources used reports a measured half-life of LL-37 in people. The Voronko review lists "low stability in biological fluids" and a "short plasma half-life" among the problems limiting clinical application, and reports a half-life of LL-37 rising from 2 hours to 24 hours with PLGA nanoparticles, citing another study without saying in which matrix or species.1 |
| Bioavailability (subcutaneous) | ~95% | None of the sources used gives a bioavailability figure for LL-37. In mice, a gallium-67 labelled LL-37 variant given subcutaneously "was absorbed systemically following a two-phase kinetic model".8 |
| Time to peak | ~30 minutes | None of the sources used reports a time to peak for LL-37. |
| Duration of activity | ~8 hours | None of the sources used reports a duration of activity for LL-37. |
| Route | SubQ | The human studies below used a solution or cream applied to ulcers, an oral bacterial preparation, or injections into tumours.2,3,4,9 |
Biodistribution in mice
Esposito and colleagues, European Journal of Pharmaceutics and Biopharmaceutics, 2024, followed a gallium-67 labelled variant of LL-37 for 48 hours in healthy mice.8 Given as an intravenous bolus of just over 20 µg, the radiotracer "was rapidly cleared from the blood, largely by the liver".8 Given subcutaneously at the same dose level, it was predominantly cleared renally.8 These are results for a labelled variant in mice, not for LL-37 in people.
Human studies
A search of PubMed on 16 November 2026 for LL-37 in the title or summary text, limited to randomized controlled trials or clinical trials, returned 60 records, and by title four of them tested LL-37 or an LL-37 bacterial preparation as the treatment. A ClinicalTrials.gov search with LL-37 as the intervention term returned 20 studies on the same date, and by title two of them list LL-37 itself as the intervention: NCT02225366 and NCT04098562.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Grönberg and colleagues, 201410 | Randomised, double-blind, placebo-controlled; 3-week open-label placebo run-in | 34 with venous leg ulcers | Twice weekly applications of 0.5, 1.6 or 3.2 mg/mL or placebo for 4 weeks, then 4 weeks of follow-up | Healing rate constants about six and three times placebo at 0.5 and 1.6 mg/mL (p = 0.003, p = 0.088); none at 3.2 mg/mL |
| Mahlapuu and colleagues, 2021 (HEAL LL-37)2 | Phase IIb, randomised, double-blind, placebo-controlled; 15 sites in Poland and Sweden | 148 treated with hard-to-heal venous leg ulcers; 144 in the full analysis set | 0.5 or 1.6 mg/mL or placebo, twice weekly for 13 weeks, with compression; 16 weeks of follow-up | Full set: complete closure 26.5%, 24.7%, 25.3% (0.5 mg/mL, 1.6 mg/mL, placebo), not significant; post hoc, ulcers of 10 cm2 or more (21–24 per group, one-sided tests): closure 28.1%, 19.6%, 8.1%, with the 0.5 mg/mL difference reported as significant (P = 0.0458) |
| Miranda and colleagues, 20233 | Randomised, double-blind, placebo-controlled; Jakarta | 25 with diabetic foot ulcers (13 LL-37 cream, 12 placebo cream) | Cream twice a week for 4 weeks | Granulation index rose more with LL-37 (p = 0.031, 0.009, 0.006, 0.037 on days 7, 14, 21, 28); wound area differences not significant on any day (p > 0.05); IL-1α and TNF-α not reduced; aerobic bacteria colonisation differences not significant (p > 0.05) |
| Zhao and colleagues, 20234 | Open-label, randomised, placebo-controlled, single centre; Omicron BA.5.1.3 | 238 adult inpatients with COVID-19 | Oral recombinant LL-37 Lactococcus lactis; dose and length not given in the summary | Negative conversion time of SARS-CoV-2 RNA 9.80 ± 2.67 with LL-37 against 14.04 ± 5.89 with placebo (p < 0.01) in patients treated within 6 days of confirmation (the summary gives no n or unit and no result for all 238); no severe adverse events observed |
| M.D. Anderson Cancer Center registry record, NCT022253669 | Phase 1 and 2, dose finding; primary outcome the optimal biological dose based on toxicity | Melanoma with cutaneous or subcutaneous tumours of at least 1 cm; enrollment listed as 4 (up to 36 planned) | Weekly injections into tumours for up to 8 weeks: 250 µg per tumour (cohort 1), 500 µg per tumour (cohort 2) | Results record: 3 started, 1 left for lack of efficacy; 0 serious events and 0 deaths; 8 non-serious adverse-event terms, including squamous cell carcinoma and actinic keratosis (cohort 1) |
Deeper analysis: HEAL LL-37, Mahlapuu and colleagues, 2021
Mahlapuu and colleagues, Wound Repair and Regeneration, 2021, enrolled men aged 18 years or over and postmenopausal women with venous or mixed ulcers of 2 to 40 cm2 that had not healed after 6 weeks of standard therapy.2 Of 190 screened, 149 were randomised 1:1:1.2 The primary objective was the incidence of complete wound closure; the authors report that the full-population analysis showed no significant improvement in healing parameters, and mean wound area fell by 35.63% with 0.5 mg/mL, 4.02% with 1.6 mg/mL and 51.69% with placebo, with none of these differences statistically significant.2
In a post hoc analysis of patients whose ulcer was at least 10 cm2 at randomisation, the odds ratio for complete closure with 0.5 mg/mL against placebo was 4.454 (P = 0.0458).2 The authors state that one-sided tests were used for the primary and secondary efficacy analyses, including subgroup analyses, and that no improvement was detected with LL-37 in patients with a wound area below 10 cm2.2
On safety, 122 adverse events were reported by 64 patients (43.2%), eight severe adverse events were reported in eight patients, and 12 non-fatal serious adverse events occurred in 11 patients (7.4%), none assessed as related to the study drug; there were no deaths.2 Six adverse events in four patients were judged possibly related to the product: wound infection and dermatitis in the 0.5 mg/mL group, peripheral swelling in the 1.6 mg/mL group and deep phlebitis in the placebo group.2 The most commonly reported events were overdose, wound infection, hypertension, underdose and erysipelas, and the total number of adverse events was slightly higher in the active groups, which the authors attribute largely to overdose, underdose and erysipelas reports.2 Five patients, all in the 1.6 mg/mL group, withdrew: two from treatment (femur fracture, deep vein thrombosis) and three from the study after their last dose (cerebrovascular accident, lower limb fracture, raised blood creatinine); the authors assessed all these events as unlikely related to the study drug.2
The authors name as the major limitation the high drop-off at the visits 8 and 16 weeks after treatment, with only 63.5% of patients attending at least one follow-up visit, and state that the trial "was not designed or powered to identify significant differences in the subgroups which were small with only 21–24 patients per group".2 The study was financed by Promore Pharma AB; three authors were employees of the company at the time, one of them a minority shareholder, and the company is developing LL-37 under the name ropocamptide.2
Deeper analysis: first-in-man venous leg ulcer trial, Grönberg and colleagues, 2014
Grönberg and colleagues, Wound Repair and Regeneration, 2014, described their trial of 34 people with venous leg ulcers as first-in-man, with a 3-week open-label placebo run-in and a 4-week randomised double-blind phase.10 The healing rate constants at 0.5 and 1.6 mg/mL were approximately six- and threefold higher than placebo (p = 0.003 and p = 0.088), and mean ulcer area decreased by 68% and 50% in those groups.10 The authors state there were "no safety concerns regarding local or systemic adverse events", while the 2021 paper describes the 3.2 mg/mL group of this trial as having "elevated frequency and severity of local reactions compared with the other groups".10,2 The record lists one author affiliation, Research and Development at Pergamum AB, Solna, Sweden, and gives no funder.10
Deeper analysis: LL-37 cream in diabetic foot ulcers, Miranda and colleagues, 2023
Miranda and colleagues, Archives of Dermatological Research, 2023, randomised 25 adults aged 18 to 60 with uninfected diabetic foot ulcers or ulcers with mild infection to LL-37 cream (13) or placebo cream (12).3 The paper states that the primary efficacy parameter was the granulation index; the ClinicalTrials.gov entry, a 2019 record that planned 40 patients, lists ten primary outcomes, among them "Changes of Healing Rate" at 1 to 4 weeks, defined as the difference in granulation index, plus bacterial counts and inflammation markers.3,11
The mean change in granulation index from day 1 to day 21 was 0.64 (± 0.30) with LL-37 and 0.30 (± 0.26) with placebo (p = 0.006).3 The differences in wound area were not significant on any day (p > 0.05).3
The authors report "no side effect directly caused by the application of LL-37 cream", and one of thirteen participants in the LL-37 group had mild irritant contact dermatitis due to excessive wound exudate.3 The authors give "the small study sample" as the main limitation, note that median IL-1α was significantly higher in the LL-37 group at baseline, and report funding from a Universitas Indonesia research grant with no role for the funders and no conflicts of interest declared.3
Deeper analysis: oral LL-37 and COVID-19, Zhao and colleagues, 2023
Zhao and colleagues, Journal of Medical Virology, 2023, studied 238 adult inpatients in an open-label, randomised, placebo-controlled, single-centre trial of a recombinant LL-37 Lactococcus lactis preparation, with negative conversion time of SARS-CoV-2 RNA and adverse events as primary end points.4 The summary reports the comparison for early treatment, in the authors' words "as early as intervened on 6th day of case confirmed": negative conversion time 9.80 ± 2.67 with LL-37 against 14.04 ± 5.89 with placebo (p < 0.01), and an adjusted hazard ratio of 2.427 (95% confidence interval 1.239 to 4.751; p = 0.0097) for LL-37 within 6 days against placebo; the summary gives no n or unit for that group.4 The summary gives no dose, schedule, funder or author ties to a sponsor, and a recombinant bacterial preparation is not the peptide given by injection, so its result is not a result for injected LL-37.4
Intratumoral injections in melanoma
The M.D. Anderson Cancer Center registry record, NCT02225366, lists an actual enrollment of 4, and its participant flow lists 3 starting across the two cohorts (2 and 1), one leaving for lack of efficacy, against up to 36 participants planned in its description.9 It reports no serious events and no deaths in either cohort and lists eight non-serious adverse-event terms: squamous cell carcinoma, actinic keratosis, anaemia, skin hypopigmentation, hypothyroidism, lymphocyte count decrease, white blood cell decrease and blood bilirubin increase.9 The posted values for the primary and secondary outcomes are 2 in cohort 1 and 1 in cohort 2, equal to the number of participants in each cohort, and the record gives no reading of them.9 The record names the National Cancer Institute as a collaborator.9 Dolkar and colleagues, Journal of Cutaneous Pathology, 2018, reported on a 63-year-old woman with stage IIIC melanoma who had 8 weekly LL-37 injections, with shrinkage of injected lesions, followed about 45 days after starting by verrucous papules and a vesiculo-bullous lesion on the trunk and extremities that resolved within 2 months of stopping.5
Doses reported in studies
The human studies in the tables report concentrations or amounts per ulcer or tumour, not a dose per person, and none of them gave LL-37 subcutaneously to people; the app's typical dose is 50–100 mcg by the subcutaneous route. The summary of the oral COVID-19 preparation gives no dose.4,5
| Study | Route and preparation | Dose reported | Schedule |
|---|---|---|---|
| Grönberg and colleagues, 201410 | Applied to venous leg ulcers | 0.5, 1.6 or 3.2 mg/mL | Twice weekly for 4 weeks |
| Mahlapuu and colleagues, 20212 | Applied to the wound bed in a polyvinyl alcohol solution, 25 µL per cm2 of ulcer | 0.5 or 1.6 mg/mL | Twice weekly for 13 weeks |
| Miranda and colleagues, 20233 | Cream, 0.025 mL per cm2 | 0.5 mg/g | Twice a week for 4 weeks |
| M.D. Anderson Cancer Center registry record, NCT022253669 | Injected into cutaneous or subcutaneous melanoma tumours | 250 µg per tumour (cohort 1), 500 µg per tumour (cohort 2) | Weekly for up to 8 weeks |
| Esposito and colleagues, 2024 (mice)8 | Intravenous bolus or subcutaneous, gallium-67 labelled variant | Just over 20 µg (intravenous bolus; subcutaneous at the same dose level) | Followed for 48 hours |
Side effects reported
In people
In the 2021 phase IIb trial, local reactions at the target ulcer included redness (42.6% of patients overall), oedema (39.2%) and raised temperature (20.3%), and reactions of the adjacent skin included redness (54.1%), scaling (52.7%), papules (19.6%), pustules (15.5%) and vesicles (4.7%).2 The authors state that most reactions were mild or moderate with no consistent difference between groups, and that severe local reactions affected at most 5 patients (3.4%) at each visit.2 Overall, 25 patients (16.9%) had more than a 50% increase in ulcer area at any post-baseline visit, with no apparent difference between groups.2 Other reports in people: local reactions in the 2014 trial's 3.2 mg/mL group, the melanoma case report's dermatologic toxicity, the melanoma registry record's eight non-serious adverse-event terms, and one case of mild irritant contact dermatitis in the cream trial.2,5,9,3
FDA's stated concerns
FDA's page states that compounded drugs containing cathelicidin LL-37 "may pose risk for immunogenicity for certain routes of administration" and may have complexities with peptide-related impurities and API characterization.6 It adds that "nonclinical research findings suggest detrimental effects on male reproduction and that this drug can be protumorigenic in some tissues".6
In cells and animals
Coffelt and colleagues, Proceedings of the National Academy of Sciences, 2009, reported that neutralising LL-37 in vivo "significantly reduces the engraftment of MSCs into ovarian tumor xenografts", resulting in inhibition of tumour growth, and concluded that LL-37 facilitates ovarian tumour progression.12 Weber and colleagues, Breast Cancer Research, 2009, found that LL-37 stimulated the migration of breast cancer cells and that overexpression of hCAP18 in a low malignant breast cancer cell line promoted metastases in SCID mice.13 Lee and colleagues, Molecular Human Reproduction, 2023, injected LL-37 at 36 µM (10 times the spermicidal dose) transcervically into female mice over three oestrous cycles and reported normal vagina, cervix and uterus histology and 100% resumption of fecundity, the same as PBS-injected controls; the authors state that similar studies have to be conducted in non-human primates and then humans, and FDA's stated concern is about male reproduction.14
Bloodwork and markers
Sources in this part
Majewski and colleagues, Journal of Biological Regulation and Homeostatic Agents, 2017, measured serum LL-37 by ELISA in 50 people with pulmonary tuberculosis, 31 with pneumonia from Gram-positive bacteria, 68 with pneumonia from Gram-negative bacteria and 61 healthy subjects, and the mean was significantly higher in the tuberculosis group than in the other three groups (p < 0.001).15 These are the body's own serum LL-37 levels, not levels after giving LL-37.15
Regulatory and anti-doping status
FDA's page on bulk drug substances for compounding, current as of 22 April 2026, lists cathelicidin LL-37 under "Bulk drug substances nominated but withdrawn", a list it describes as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators".6 The entry states that "FDA lacks sufficient safety-related information regarding cathelicidin LL-37 to know whether the drug would cause harm when administered to humans".6 FDA's introduction to the briefing documents for the 23 to 24 July 2026 Pharmacy Compounding Advisory Committee meeting names BPC-157, KPV, TB-500, MOTS-c, emideltide, epitalon and semax as the substances under consideration, and LL-37 is not among them.16
A search of DailyMed on 16 November 2026 for LL-37, ropocamptide and cathelicidin returned 0 labels. The 2024 review by Dzurová and colleagues states, on the clinical use of antimicrobial peptides: "only a few AMPs are currently in clinical use, and none of these are cathelicidins".17
The WADA 2026 Prohibited List does not contain the names LL-37 or cathelicidin.18 Its class S0 prohibits at all times any pharmacological substance not addressed elsewhere in the list "with no current approval by any governmental regulatory health authority for human therapeutic use".18 The list does not state whether S0 applies to LL-37.18
What is not known
Sources in this part
- The sources report no measured half-life, bioavailability, time to peak or duration of activity of LL-37 in people, so none of the app's figures for them rests on a measured value in these sources.1 The Voronko review mentions a half-life of 2 hours for LL-37 from another study, with matrix and species not stated.1
- The phase IIb trial, the largest trial of the peptide itself in the tables, reported no significant benefit in its full population, and its finding in ulcers of at least 10 cm2 was post hoc, in groups of 21 to 24 patients, with the authors calling for a further adequately powered study.2
- The 2025 Voronko review states that for modified cathelicidins, further research is required to optimise design, ensure cost-effective production and "validate long-term safety and efficacy".1
Frequently asked questions
What is LL-37?
What is the half-life of LL-37?
The app lists a half-life of about 4 hours, and the sources report no measured half-life of LL-37 in people. A 2025 review lists "low stability in biological fluids" and a "short plasma half-life" among the problems limiting clinical application, and reports a half-life of LL-37 rising from 2 hours to 24 hours with PLGA nanoparticles, citing another study without saying in which matrix or species.1
Is LL-37 FDA approved?
A search of DailyMed on 16 November 2026 for LL-37, ropocamptide and cathelicidin returned 0 labels. A 2024 review states, on the clinical use of antimicrobial peptides, that "only a few AMPs are currently in clinical use, and none of these are cathelicidins".17
What does FDA say about compounded LL-37?
FDA's compounding page lists cathelicidin LL-37 among bulk drug substances nominated but withdrawn, previously in category 2, and states that FDA lacks sufficient safety-related information about it.6
Is LL-37 banned by WADA?
The WADA 2026 Prohibited List does not name LL-37 or cathelicidin.18 Class S0 prohibits at all times substances with "no current approval by any governmental regulatory health authority for human therapeutic use" that are not addressed elsewhere in the list, and the list does not state whether it applies to LL-37.18
What did the HEAL LL-37 trial find?
In HEAL LL-37, a phase IIb trial of 148 treated patients with venous leg ulcers, the full-population analysis did not identify any significant improvement in healing with LL-37 against placebo.2 A post hoc analysis in ulcers of at least 10 cm2, in subgroups of 21 to 24 patients that the trial was not powered to test, reported complete closure in 28.1% with 0.5 mg/mL, 19.6% with 1.6 mg/mL and 8.1% with placebo, with the 0.5 mg/mL difference reported as significant (P = 0.0458), and the trial was financed by Promore Pharma AB.2
Has LL-37 been injected in people?
A registry record from M.D. Anderson Cancer Center describes weekly injections into melanoma tumours at 250 µg and 500 µg per tumour for up to 8 weeks; the record shows 3 people starting against up to 36 planned and lists no serious events.9 A case report on injections used in a phase 1 trial described dermatologic toxicity in a woman who had progressed on nivolumab and chemotherapy and received 8 weekly injections; the lesions appeared about 45 days after starting and resolved within 2 months of stopping.5
What side effects were reported in LL-37 studies?
In the 2021 trial, 122 adverse events were reported by 64 of 148 patients (43.2%), most often overdose, wound infection, hypertension, underdose and erysipelas, with a slightly higher total in the active groups; 12 serious adverse events occurred in 11 patients, and none of the serious events was assessed as related to the study drug.2 The cream trial reported one participant of thirteen with mild irritant contact dermatitis due to excessive wound exudate.3
Guides, tools and comparisons
References
- Voronko OE, Khotina VA, Kashirskikh DA, Lee AA, Gasanov VAO. Antimicrobial peptides of the cathelicidin family: focus on LL-37 and its modifications. Int J Mol Sci 2025. PMC12386566
- Mahlapuu M, Sidorowicz A, Mikosinski J, et al. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: a multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen 2021. PMC9298190
- Miranda E, Bramono K, Yunir E, et al. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res 2023. PMC10514151
- Zhao Y, Zhang H, Zhao Z, et al. Efficacy and safety of oral LL-37 against the Omicron BA.5.1.3 variant of SARS-CoV-2: a randomized trial. J Med Virol 2023. PMID 37605995
- Dolkar T, Trinidad CM, Nelson KC, et al. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: a detailed examination of the clinicopathologic features. J Cutan Pathol 2018. PMID 29665030
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Content current as of 22 April 2026. FDA page
- Vandamme D, Landuyt B, Luyten W, Schoofs L. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 2012. PMID 23246832
- Esposito TVF, Rodríguez-Rodríguez C, Blackadar C, et al. Biodistribution of the cationic host defense peptide LL-37 using SPECT/CT. Eur J Pharm Biopharm 2024. PMID 38972467
- M.D. Anderson Cancer Center. Intratumoral injections of LL37 for melanoma. ClinicalTrials.gov NCT02225366. NCT02225366
- Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair Regen 2014. PMID 25041740
- Fakultas Kedokteran Universitas Indonesia. Efficacy of LL-37 cream on bacteria colonization, inflammation response and healing rate of diabetic foot ulcers. ClinicalTrials.gov NCT04098562. NCT04098562
- Coffelt SB, Marini FC, Watson K, et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A 2009. PMID 19234121
- Weber G, Chamorro CI, Granath F, et al. Human antimicrobial protein hCAP18/LL-37 promotes a metastatic phenotype in breast cancer. Breast Cancer Res 2009. PMID 19183447
- Lee SG, Kiattiburut W, Burke Schinkel SC, Angel J, Tanphaichitr N. Safety of multiple administrations of spermicidal LL-37 antimicrobial peptide into the mouse female reproductive tract. Mol Hum Reprod 2023. PMID 37326833
- Majewski K, Agier J, Kozłowska E, Brzezińska-Błaszczyk E. Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases. J Biol Regul Homeost Agents 2017. PMID 28956425
- US Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee meeting, 23 to 24 July 2026 (introduction). FDA briefing document (introduction)
- Dzurová L, Holásková E, Pospíšilová H, Schneider Rauber G, Frébortová J. Cathelicidins: opportunities and challenges in skin therapeutics and clinical translation. Antibiotics (Basel) 2024. PMC11762488
- World Anti-Doping Agency. The 2026 Prohibited List. International Standard, in effect 1 January 2026. WADA 2026 Prohibited List